环氧合酶-2与非酒精性脂肪性肝炎关系的研究进展

王亮; 张岭漪

环氧合酶-2与非酒精性脂肪性肝炎关系的研究进展

王亮,
张岭漪

兰州大学第二医院肝病科甘肃省消化肿瘤重点实验室

基金项目:

甘肃省科学事业费科技项目(QS012-C33-41)；兰州大学第二医院院内基金(YJ2010-09)；

详细信息

中图分类号: R575.1
计量
- 文章访问数: 3153
- HTML全文浏览量: 7
- PDF下载量: 997
- 被引次数: 0
出版历程
- 出版日期: 2012-08-20

Cyclooxygenase-2 and nonalcoholic steatohepatitis

Research funding:

摘要

摘要: 非酒精性脂肪性肝炎（NASH）呈慢性肝脏脂毒性炎症表现,是非酒精性脂肪性肝病（NAFLD）的重要转折点,存在肝病重症化趋势。环氧合酶-2（COX-2）作为启动炎症反应的关键酶同样涉及到NASH的形成及进展。本文就COX-2及其抑制剂与NASH关系的研究予以综述。
- 环氧化酶-2 /
- 脂肪肝
Abstract: Nonalcoholic steatohepatitis (NASH) is characterized by chronic states of fatty liver infiltration and lipotoxic inflammation.NASH is considered a critical process for the progression of non-alcoholic fatty liver disease (NAFLD) to the severe stage.Cyclooxygenase-2 (COX-2) , a key pro-inflammatory factor, has been implicated in NASH pathogenesis.In this review, we discuss the recent findings concerning both the role of COX-2 in NASH and the potential therapeutic promise of COX-2 inhibitors.
- cyclooxygenase 2 /
- fatty liver

HTML全文

参考文献(23)

[1]Petta S, Muratore C, CraxìA.Non-alcoholic fatty liver dis-ease pathogenesis:the present and the future[J].DigestLiver Dis, 2009, 41 (9) :615-625.

[2]Starley BQ, Calcagno CJ, Harrison SA, et al.Nonalcoholicfatty liver disease and hepatocellular carcinoma:A weightyconnection[J].Hepatology, 2010, 51 (5) :1820-1832.

[3]Liedtke AJ, Crews BA, Daniel CM, et al.Cyclooxygenase-1-selective inhibitors based on the (E) -2'-des-methyl-sulindac sulfide scaffold[J].J Med Chem, 2012, 55 (5) :2287-2300.

[4]Cave M, Deaciuc I, Mendez C, et al.Nonalcoholic fatty liverdisease:predisposing factors and the role of nutrition[J].JNutr Biochem, 2007, 18 (3) :184-195.

[5]Tsatsanis C, Zacharioudaki V, Androulidaki A, et al.Adipone-ctin induces TNF-alpha and IL-6 in macrophages and pro-motes tolerance to itself and other pro-inflammatory stimuli[J].Biochem Biophys Res Commun, 2005, 335 (4) :1254-1263.

[6]Krawczyk M, Bonfrate L, Portincasa P.Nonalcoholic fatty liverdisease[J].Best Pract Res Cl Ga, 2010, 24 (5) :695-708.

[7]Choi S, Diehl AM.Role of inflammation in nonalcoholic steato-hepatitis[J].Curr Opin Gastroen, 2005, 21 (6) :702-707.

[8]Yu J, Ip E, Dela Pena A, et al.COX-2 induction in mice withexperimental nutritional steatohepatitis:Role as Pro-inflamma-tory Mediator[J].Hepatology, 2006, 43 (4) :826-836.

[9]Giannitrapani L, Ingrao S, Soresi M, et al.Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carci-noma[J].Ann NY Acad Sci, 2009, 1155:293-299.

[10]Chandrasekharan NV, Dai H, Roos KL, et al.COX-3, acy-cloxygenase-l variant inhibited by acetaminophen and otheranalgesic antipyretic drugs:Cloning, structure, and expres-sion[J].Proc Nad Acad Sci USA, 2002, 99 (21) :13926-13931.

[11]Cao MB, Dong L, Lu XL, et al.Expression of cyclooxygenase-2 and its pathogenic effects in nonalcoholic fatty liver dis-ease[J].J Nanjin Med Univ, 2008, 22 (2) :111-116.

[12]Chen J, Liu D, Bai Q, et al.Celecoxib attenuates liver steatosisand inflammation in non-alcoholic steatohepatitis induced byhigh-fat diet in rats[J].Mol Med Rep, 2011, 4 (5) :811-816.

[13]Shanab AA, Scully P, Crosbie O, et al.Small intestinal bac-terial overgrowth in nonalcoholic steatohepatitis:associationwith toll-like receptor 4 expression and plasma levels of in-terleukin 8[J].Dig Dis Sci, 2011, 56 (5) :1524-1534.

[14]刘近春, 张志岗, 柴宝, 等.甘氨酸对NASH大鼠肝组织环氧合酶-2表达的影响[J].实用肝脏病杂志, 2009, 12 (2) :84-86.

[15]Tokyay R, Kaya E, Gur ES, et al.Prostaglandin synthetaseinhibition reduces peritonitis-induced early liver oxidantstress[J].Surg Today, 1999, 29 (1) :42-46.

[16]Fu JY, Masferrer JL, Seibert K, et al.The induct ion andsuppression of prostaglandin H2 synthases (cyclooxygen-ase) in human monocytes[J].J Biol Chem, 1990, 265 (28) :16737-16740.

[17]Hsieh PS, Jin JS, Chiang CF, et al.COX-2-mediated in-flammation in fat is crucial for obesity-linked insulin resist-ance and fatty liver[J].Obesity, 2009, 17 (6) :1150-1157.

[18]Garonna E, Botham KM, Birdsey GM, et al.Vascular endo-thelial growth factor receptor-2 couples cyclo-oxygenase-2 with proangiogenic actions of leptin on human endothelialcells[J].PLoS One, 2011, 18, 6 (4) :e18823.

[19]Nishina S, Hino K, Korenaga M, et al.Hepatitis C virus-in-duced reactive oxygen species raise hepatic iron level in miceby reducing hepcidin transcription[J].Gastroenterology, 2008, 134 (1) :226-238.

[20]Trombini P, Piperno A.Ferritin, metabolic syndrome and NAFLD:elective attractions and dangerous lilaisons[J].J Hepatol, 2007, 46 (4) :549-552.

[21]Esposito E, Iacono A, Bianco G, et al.Probiotics reduce theinflammatory response induced by a high-fat diet in the liverof young rats[J].J Nutr, 2009, 139 (5) :905-911.

[22]Lu S, Archer MC.Celecoxib decreases fatty acid synthaseexpression via down-regulation of c-Jun N-terminal ki-nase-1[J].Exp Biol Med (Maywood) , 2007, 232 (5) :643-653.

[23]Mohamed I, Entesar F, Wafaey G, et al.Nitro-aspirin is apotential therapy for non alcoholic fatty liver disease[J].EurJ Pharmacol, 2011, 659 (2-3) :289-295.

施引文献

资源附件(0)

访问统计